- Home
- OPT vs ENX Comparison
OPT vs ENX Comparison
Compare OPT & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- ENX
- Stock Information
- Founded
- OPT 1984
- ENX 2002
- Country
- OPT Australia
- ENX United States
- Employees
- OPT N/A
- ENX N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- ENX Finance/Investors Services
- Sector
- OPT Health Care
- ENX Finance
- Exchange
- OPT Nasdaq
- ENX Nasdaq
- Market Cap
- OPT 201.5M
- ENX 178.4M
- IPO Year
- OPT 2020
- ENX N/A
- Fundamental
- Price
- OPT $3.24
- ENX $10.03
- Analyst Decision
- OPT Strong Buy
- ENX
- Analyst Count
- OPT 2
- ENX 0
- Target Price
- OPT $14.00
- ENX N/A
- AVG Volume (30 Days)
- OPT 10.8K
- ENX 25.4K
- Earning Date
- OPT 08-30-2024
- ENX 01-01-0001
- Dividend Yield
- OPT N/A
- ENX 3.94%
- EPS Growth
- OPT N/A
- ENX N/A
- EPS
- OPT N/A
- ENX 0.16
- Revenue
- OPT $261,859.00
- ENX N/A
- Revenue This Year
- OPT N/A
- ENX N/A
- Revenue Next Year
- OPT $55,563.16
- ENX N/A
- P/E Ratio
- OPT N/A
- ENX $61.00
- Revenue Growth
- OPT N/A
- ENX N/A
- 52 Week Low
- OPT $1.60
- ENX $7.84
- 52 Week High
- OPT $4.40
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- OPT 70.30
- ENX 61.72
- Support Level
- OPT $2.84
- ENX $9.86
- Resistance Level
- OPT $3.19
- ENX $10.09
- Average True Range (ATR)
- OPT 0.14
- ENX 0.07
- MACD
- OPT 0.01
- ENX 0.01
- Stochastic Oscillator
- OPT 100.00
- ENX 82.61
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.